JPWO2022159463A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2022159463A5 JPWO2022159463A5 JP2023539784A JP2023539784A JPWO2022159463A5 JP WO2022159463 A5 JPWO2022159463 A5 JP WO2022159463A5 JP 2023539784 A JP2023539784 A JP 2023539784A JP 2023539784 A JP2023539784 A JP 2023539784A JP WO2022159463 A5 JPWO2022159463 A5 JP WO2022159463A5
- Authority
- JP
- Japan
- Prior art keywords
- compound
- optionally substituted
- independently
- branched
- cells
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 150000001875 compounds Chemical class 0.000 claims 30
- 238000000034 method Methods 0.000 claims 21
- 229920006395 saturated elastomer Polymers 0.000 claims 20
- 238000002360 preparation method Methods 0.000 claims 16
- 125000001183 hydrocarbyl group Chemical group 0.000 claims 15
- 239000003795 chemical substances by application Substances 0.000 claims 11
- 230000000069 prophylactic effect Effects 0.000 claims 11
- 230000001225 therapeutic effect Effects 0.000 claims 11
- 210000004027 cell Anatomy 0.000 claims 8
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 6
- 125000000325 methylidene group Chemical group [H]C([H])=* 0.000 claims 6
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims 5
- 125000001931 aliphatic group Chemical group 0.000 claims 5
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims 5
- 125000005842 heteroatom Chemical group 0.000 claims 5
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims 5
- 229910052757 nitrogen Inorganic materials 0.000 claims 5
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims 5
- 239000001301 oxygen Chemical group 0.000 claims 5
- 229910052760 oxygen Inorganic materials 0.000 claims 5
- 229920001184 polypeptide Polymers 0.000 claims 5
- 102000004196 processed proteins & peptides Human genes 0.000 claims 5
- 108090000765 processed proteins & peptides Proteins 0.000 claims 5
- 229910052717 sulfur Chemical group 0.000 claims 5
- 239000011593 sulfur Chemical group 0.000 claims 5
- 108091032973 (ribonucleotides)n+m Proteins 0.000 claims 4
- 201000010099 disease Diseases 0.000 claims 4
- 239000001257 hydrogen Substances 0.000 claims 4
- 229910052739 hydrogen Inorganic materials 0.000 claims 4
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims 4
- 150000003839 salts Chemical class 0.000 claims 4
- 150000002632 lipids Chemical class 0.000 claims 3
- 210000004962 mammalian cell Anatomy 0.000 claims 3
- 108020004999 messenger RNA Proteins 0.000 claims 3
- 239000000203 mixture Substances 0.000 claims 3
- 210000000056 organ Anatomy 0.000 claims 3
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 3
- 230000003393 splenic effect Effects 0.000 claims 3
- -1 1-adamantyl Chemical group 0.000 claims 2
- 125000003670 adamantan-2-yl group Chemical group [H]C1([H])C(C2([H])[H])([H])C([H])([H])C3([H])C([*])([H])C1([H])C([H])([H])C2([H])C3([H])[H] 0.000 claims 2
- 125000002837 carbocyclic group Chemical group 0.000 claims 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 claims 2
- 208000035475 disorder Diseases 0.000 claims 2
- 125000000623 heterocyclic group Chemical group 0.000 claims 2
- 230000002401 inhibitory effect Effects 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- 210000001616 monocyte Anatomy 0.000 claims 2
- 239000002105 nanoparticle Substances 0.000 claims 2
- 108020004707 nucleic acids Proteins 0.000 claims 2
- 102000039446 nucleic acids Human genes 0.000 claims 2
- 150000007523 nucleic acids Chemical class 0.000 claims 2
- 125000000843 phenylene group Chemical group C1(=C(C=CC=C1)*)* 0.000 claims 2
- 125000006570 (C5-C6) heteroaryl group Chemical group 0.000 claims 1
- 125000003627 8 membered carbocyclic group Chemical group 0.000 claims 1
- 239000002202 Polyethylene glycol Substances 0.000 claims 1
- 210000001744 T-lymphocyte Anatomy 0.000 claims 1
- 230000033289 adaptive immune response Effects 0.000 claims 1
- 125000003118 aryl group Chemical group 0.000 claims 1
- 125000004429 atom Chemical group 0.000 claims 1
- 210000003719 b-lymphocyte Anatomy 0.000 claims 1
- 210000001185 bone marrow Anatomy 0.000 claims 1
- 210000002798 bone marrow cell Anatomy 0.000 claims 1
- 125000004452 carbocyclyl group Chemical group 0.000 claims 1
- 210000004413 cardiac myocyte Anatomy 0.000 claims 1
- 210000003169 central nervous system Anatomy 0.000 claims 1
- 235000012000 cholesterol Nutrition 0.000 claims 1
- 125000004980 cyclopropylene group Chemical group 0.000 claims 1
- 210000002064 heart cell Anatomy 0.000 claims 1
- 210000003958 hematopoietic stem cell Anatomy 0.000 claims 1
- 210000003494 hepatocyte Anatomy 0.000 claims 1
- 125000005549 heteroarylene group Chemical group 0.000 claims 1
- 210000002865 immune cell Anatomy 0.000 claims 1
- 230000001939 inductive effect Effects 0.000 claims 1
- 210000003292 kidney cell Anatomy 0.000 claims 1
- 210000005229 liver cell Anatomy 0.000 claims 1
- 210000000663 muscle cell Anatomy 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 150000003904 phospholipids Chemical class 0.000 claims 1
- 229920001223 polyethylene glycol Polymers 0.000 claims 1
- 210000004989 spleen cell Anatomy 0.000 claims 1
- 238000002255 vaccination Methods 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163139734P | 2021-01-20 | 2021-01-20 | |
| US63/139,734 | 2021-01-20 | ||
| PCT/US2022/012941 WO2022159463A1 (en) | 2021-01-20 | 2022-01-19 | Nanomaterials |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2024502954A JP2024502954A (ja) | 2024-01-24 |
| JPWO2022159463A5 true JPWO2022159463A5 (https=) | 2025-01-24 |
| JP2024502954A5 JP2024502954A5 (https=) | 2025-01-24 |
Family
ID=82549752
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023539784A Pending JP2024502954A (ja) | 2021-01-20 | 2022-01-19 | ナノ材料 |
Country Status (10)
| Country | Link |
|---|---|
| US (2) | US12059477B2 (https=) |
| EP (1) | EP4281050A4 (https=) |
| JP (1) | JP2024502954A (https=) |
| KR (1) | KR20230131863A (https=) |
| CN (1) | CN116761888A (https=) |
| AU (1) | AU2022210313A1 (https=) |
| CA (1) | CA3203742A1 (https=) |
| IL (1) | IL303846A (https=) |
| MX (1) | MX2023008333A (https=) |
| WO (1) | WO2022159463A1 (https=) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US12569438B2 (en) | 2019-07-29 | 2026-03-10 | Georgia Tech Research Corporation | Nanomaterials containing constrained lipids and uses thereof |
| US12435035B2 (en) | 2020-01-09 | 2025-10-07 | Guide Therapeutics, Llc | Nanomaterials |
| IL303845A (en) | 2021-01-20 | 2023-08-01 | Beam Therapeutics Inc | Nanomaterials include a degradable property |
| JP2024503441A (ja) * | 2021-01-20 | 2024-01-25 | ビーム セラピューティクス インク． | イオン化可能な脂質を含むナノ材料 |
| KR20230131863A (ko) | 2021-01-20 | 2023-09-14 | 빔 테라퓨틱스, 인크. | 나노물질 |
| WO2024019936A1 (en) | 2022-07-20 | 2024-01-25 | Beam Therapeutics Inc. | Nanomaterials comprising triols |
| US12311033B2 (en) | 2023-05-31 | 2025-05-27 | Capstan Therapeutics, Inc. | Lipid nanoparticle formulations and compositions |
Family Cites Families (38)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5110977A (en) | 1990-02-14 | 1992-05-05 | Eastman Kodak Company | Ester-containing quaternary ammonium salts as adhesion improving toner charge agents |
| US20030083272A1 (en) | 1997-09-19 | 2003-05-01 | Lahive & Cockfield, Llp | Sense mrna therapy |
| AU2009238175C1 (en) | 2008-04-15 | 2023-11-30 | Arbutus Biopharma Corporation | Novel lipid formulations for nucleic acid delivery |
| KR102451116B1 (ko) | 2011-10-27 | 2022-10-06 | 메사추세츠 인스티튜트 오브 테크놀로지 | 약물 캡슐화 마이크로스피어를 형성할 수 있는, ｎ-말단 상에 관능화된 아미노산 유도체 |
| EP3608308B1 (en) | 2013-03-08 | 2021-07-21 | Novartis AG | Lipids and lipid compositions for the delivery of active agents |
| US20150165054A1 (en) | 2013-12-12 | 2015-06-18 | President And Fellows Of Harvard College | Methods for correcting caspase-9 point mutations |
| EP4019506A1 (en) | 2013-12-19 | 2022-06-29 | Novartis AG | Lipids and lipid compositions for the delivery of active agents |
| ES2895651T3 (es) | 2013-12-19 | 2022-02-22 | Novartis Ag | Lípidos y composiciones lipídicas para la administración de agentes activos |
| US10125092B2 (en) | 2014-09-05 | 2018-11-13 | Novartis Ag | Lipids and lipid compositions for the delivery of active agents |
| DK3297637T3 (da) * | 2015-05-21 | 2021-08-02 | Ohio State Innovation Foundation | Benzen-1,3,5-tricarboxamidderivater og anvendelser deraf |
| EP4286012A3 (en) | 2015-09-17 | 2024-05-29 | ModernaTX, Inc. | Compounds and compositions for intracellular delivery of therapeutic agents |
| JP7109784B2 (ja) | 2015-10-23 | 2022-08-01 | プレジデント アンド フェローズ オブ ハーバード カレッジ | 遺伝子編集のための進化したＣａｓ９蛋白質 |
| KR102547316B1 (ko) | 2016-08-03 | 2023-06-23 | 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 | 아데노신 핵염기 편집제 및 그의 용도 |
| WO2019008441A1 (en) | 2017-07-04 | 2019-01-10 | Intocell, Inc. | COMPOUNDS COMPRISING A CLIABABLE BIT AND USES THEREOF |
| EP3704262B1 (en) | 2017-10-30 | 2024-03-20 | Georgia Tech Research Corporation | Multiplexed analysis of materials for tissue delivery |
| WO2019099501A1 (en) | 2017-11-14 | 2019-05-23 | Ohio State Innovation Foundation | Benzene-1,3,5-tricarboxamide derived ester lipids and uses thereof |
| WO2020072605A1 (en) | 2018-10-02 | 2020-04-09 | Intellia Therapeutics, Inc. | Ionizable amine lipids |
| IL314386A (en) | 2018-12-05 | 2024-09-01 | Intellia Therapeutics Inc | amine modified lipids |
| JP7636330B2 (ja) | 2019-01-17 | 2025-02-26 | ジョージア テック リサーチ コーポレイション | 酸化コレステロールを含有する薬物送達システム |
| KR20210139265A (ko) | 2019-02-13 | 2021-11-22 | 빔 테라퓨틱스, 인크. | 표적 서열에서 핵염기를 변형하기 위한 아데노신 데아미나제 염기 편집기 및 이의 사용 방법 |
| WO2020219876A1 (en) | 2019-04-25 | 2020-10-29 | Intellia Therapeutics, Inc. | Ionizable amine lipids and lipid nanoparticles |
| CN114144173A (zh) | 2019-06-05 | 2022-03-04 | 盖德治疗公司 | 用于组织递送的材料的分析 |
| US12569438B2 (en) | 2019-07-29 | 2026-03-10 | Georgia Tech Research Corporation | Nanomaterials containing constrained lipids and uses thereof |
| US20220259597A1 (en) | 2019-07-29 | 2022-08-18 | Georgia Tech Research Corporation | Oligonucleotide antagonists for rna guided genome editing |
| JP7699128B2 (ja) | 2019-12-06 | 2025-06-26 | ガイド セラピューティクス，エルエルシー | ナノマテリアル |
| US12435035B2 (en) | 2020-01-09 | 2025-10-07 | Guide Therapeutics, Llc | Nanomaterials |
| MX2023007137A (es) | 2020-12-21 | 2023-08-28 | Beam Therapeutics Inc | Nanomateriales que comprenden acetales unidos a ésteres. |
| CN116782913A (zh) | 2020-12-21 | 2023-09-19 | 比姆医疗股份有限公司 | 包括缩醛的纳米材料 |
| WO2022140239A1 (en) | 2020-12-21 | 2022-06-30 | Beam Therapeutics Inc. | Nanomaterials comprising carbonates |
| IL303845A (en) | 2021-01-20 | 2023-08-01 | Beam Therapeutics Inc | Nanomaterials include a degradable property |
| JP2024503441A (ja) | 2021-01-20 | 2024-01-25 | ビーム セラピューティクス インク． | イオン化可能な脂質を含むナノ材料 |
| AU2022210299A1 (en) | 2021-01-20 | 2023-06-29 | Beam Therapeutics Inc. | Ionizable lipids for nanomaterials |
| KR20230131863A (ko) | 2021-01-20 | 2023-09-14 | 빔 테라퓨틱스, 인크. | 나노물질 |
| CA3241488A1 (en) | 2021-12-20 | 2023-06-29 | Beam Therapeutics Inc. | Ionizable amine lipids and lipid nanoparticles |
| EP4452930A1 (en) | 2021-12-20 | 2024-10-30 | Beam Therapeutics Inc. | Ionizable amine and ester lipids and lipid nanoparticles |
| EP4452925A1 (en) | 2021-12-20 | 2024-10-30 | Beam Therapeutics Inc. | Nanomaterial comprising diamines |
| EP4452942A1 (en) | 2021-12-20 | 2024-10-30 | Beam Therapeutics Inc. | Nanomaterials comprising disulfides |
| WO2023121971A1 (en) | 2021-12-20 | 2023-06-29 | Beam Therapeutics Inc. | Nanomaterials comprising tetravalent lipid compounds |
-
2022
- 2022-01-19 KR KR1020237024632A patent/KR20230131863A/ko active Pending
- 2022-01-19 CN CN202280009717.5A patent/CN116761888A/zh active Pending
- 2022-01-19 CA CA3203742A patent/CA3203742A1/en active Pending
- 2022-01-19 WO PCT/US2022/012941 patent/WO2022159463A1/en not_active Ceased
- 2022-01-19 IL IL303846A patent/IL303846A/en unknown
- 2022-01-19 MX MX2023008333A patent/MX2023008333A/es unknown
- 2022-01-19 AU AU2022210313A patent/AU2022210313A1/en active Pending
- 2022-01-19 JP JP2023539784A patent/JP2024502954A/ja active Pending
- 2022-01-19 US US17/579,115 patent/US12059477B2/en active Active
- 2022-01-19 EP EP22743085.7A patent/EP4281050A4/en active Pending
-
2024
- 2024-06-24 US US18/751,931 patent/US20250041441A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7075669B2 (ja) | 核酸送達用カチオン性脂質及びその調製物 | |
| US20230357133A1 (en) | Nanomaterials comprising carbonates | |
| JPWO2022140252A5 (https=) | ||
| IL323753A (en) | Amino lipid, and lipid nanoparticles and use thereof | |
| JPWO2022159472A5 (https=) | ||
| JPWO2022159475A5 (https=) | ||
| KR20250166967A (ko) | 이온화 가능 지질 분자 및 그 제조 방법과 용도 | |
| JPWO2022159463A5 (https=) | ||
| KR20250149165A (ko) | 아미노 지질 화합물, 및 이의 제조 방법 및 이의 용도 | |
| JPWO2022159421A5 (https=) | ||
| JP2025538575A (ja) | 核酸送達用シクロアルカン系脂質化合物及びそれを含む脂質ナノ粒子 | |
| CN120225500A (zh) | 用于活性物质递送的脂质化合物及组合物 | |
| JPWO2023121971A5 (https=) | ||
| JPWO2023121975A5 (https=) | ||
| EP4603475A1 (en) | Amino lipid compound and lipid nanoparticle for delivering bioactive ingredient | |
| KR101239492B1 (ko) | 폴리소르비톨계 삼투압적 활성 전달체 및 이를 이용한 유전자 치료 | |
| US20250001002A1 (en) | Compositions for delivery of mrna | |
| CN118146262A (zh) | 含多个叔氨基结构的双磷脂酰胺化合物及其组合物和用途 | |
| JPWO2022140238A5 (https=) | ||
| CN114828830A (zh) | 药物组合物及处置剂 | |
| EP4556460A1 (en) | Amino lipid compound, preparation method therefor, composition thereof and application thereof | |
| CN121729406A (zh) | 具有提高的稳定性的可生物降解的氨基甲酸酯脂质 | |
| CN119490447A (zh) | 药物递送材料及其应用 | |
| CN115998899A (zh) | 一种IL-11Rα靶向囊泡药物及其制备方法与应用 | |
| US20010056074A1 (en) | Novel lipophilic compounds having affinity with nucleic acids and therapeutical uses thereof |